Arthritis Rheumatol 2025 May
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Related Questions
New comment by at Uniformed Services University of the Health Sciences (USUHS) ( September 14, 2025)
@Nancy L. Carteron: I like how you bring up the concept of "deep tissue B-cell depletion." Theoretically, it should be important in Sjogren's. I can't wait to see what C...